Drive Therapeutics

Addressing Unmet Patient Needs in Retinal Disease

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chapel Hill, NC, USA
  • Currency USD
  • Founded November 2019
  • Employees 3
  • Incorporation Type LLC
  • Website drivetherapeutics.com

Company Summary

Drive Therapeutics, LLC, has developed stable, non-immunogenic, candidate molecules against a number novel targets in the progression of retinal diseases. These molecules can be used by themselves or in conjunction with existing therapies to achieve greater therapeutic efficacy while reducing the dosing regimen, resulting in better patient outcomes.

Team

  • Ryan Quick
    Co-founder, COO

    Small business owner and experienced leader in large and small scale aptamer manufacturing and analytical
    Formerly, Head of Research Chemistry, Vitrisa Therapeutics
    Director of Analytical Development and Validation, Novan

  • Matthew Levy
    Co-founder, CSO

    Expert in aptamer development and translation
    Formerly, Head of Discovery, Vitrisa Therapeutics
    Assoc. Prof. of Biochemistry, Albert Einstein College of Medicine

Advisors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free